Results from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: The phase 2 prospective CLORIC trial

Haematologica

Volumn 99, Issue 9, 2014, Pages 1486-1491

  Chevallier, Patrice ^a   Labopin, Myriam ^b,c,d   Socié, Gérard ^e   Tabrizi, Reza ^f   Furst, Sabine ^g   Lioure, Bruno ⁱ   Guillaume, Thierry ^a   Delaunay, Jacques ^a   de La Tour, Régis Peffault ^e   Vigouroux, Stéphane ^f   El Cheikh, Jean ^g   Blaise, Didier ^g   Michallet, Mauricette ^h   Bilger, Karin ⁱ   Milpied, Noel ^f   Moreau, Philippe ^a   Mohty, Mohamad ^a,b,c,d  

^a HÔTEL DIEU   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c INSERM   (France)

^d HÔPITAL SAINT ANTOINE   (France)

^e SAINT LOUIS HOSPITAL   (France)

^f BORDEAUX UNIVERSITY HOSPITAL   (France)

^g INSTITUT PAOLI CALMETTES   (France)

^h HOSPICES CIVILS DE LYON   (France)

ⁱ UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CLOFARABINE; CYCLOSPORIN; RITUXIMAB; THYMOCYTE ANTIBODY; ADENINE NUCLEOTIDE; ARABINONUCLEOSIDE; LYMPHOCYTE ANTIBODY; MYELOABLATIVE AGENT;

ACUTE BIPHENOTYPIC LEUKEMIA; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; ASPERGILLOSIS; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; ENGRAFTMENT; FEMALE; GRAFT VERSUS HOST REACTION; HAND FOOT SYNDROME; HUMAN; LEUKEMIA; LEUKEMIA RELAPSE; LYMPHOMA; MALE; MIDDLE AGED; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; SEPSIS; AGED; ALLOTRANSPLANTATION; CLINICAL TRIAL; CONTROLLED STUDY; DRUG ADMINISTRATION; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA, BIPHENOTYPIC, ACUTE; LEUKEMIA, MYELOID, ACUTE; MORTALITY; MYELODYSPLASTIC SYNDROMES; PATHOLOGY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SURVIVAL;

ADENINE NUCLEOTIDES; ADULT; AGED; ANTILYMPHOCYTE SERUM; ARABINONUCLEOSIDES; BUSULFAN; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, BIPHENOTYPIC, ACUTE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; MYELODYSPLASTIC SYNDROMES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENCE; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84907363834     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.108563     Document Type: Article

References (41)

1. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non malignant hematologic diseases. Blood. 1998;91(3):756-63.
2. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001;97(11):3390-400.
3. Giralt S, Estey E, Albitar M, van Besien K, Rondon G, Anderlini P, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997;89(12):4531-6.
4. Passweg JR, Baldomero H, Gratwohl A, Bregni M, Cesaro S, Dreger P, et al. The EBMT activity survey: 1990-2010. Bone Marrow Transplant. 2012;47(7):906-23.
5. Blaise D, Castagna L. Do different conditioning regimens really make a difference? Hematology Am Soc Hematol Educ Program. 2012;237-45.
6. Michallet M, Le Q, Mohty M, Prebet T, Nicolini F, Boiron JM, et al. Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire. Exp Hematol. 2008;36(5):535-44.
7. Blaise D, Tabrizi R, Boher JM, Le Coroller-Soriano AG, Bay JO, Fegueux N, et al. Randomized study of 2 reduced-intensity conditioning strategies for human leukocyte antigen-matched, related allogeneic peripheral blood stem cell transplantation: prospective clinical and socioeconomic evaluation. Cancer. 2013;119(3):602-11.
8. Lioure B, Bene MC, Pigneux A, Huynh A, Chevallier P, Fegueux N, et al. Early matched sibling hematopoietic cell transplantation for adult AML in first remission using an age-adapted strategy: long-term results of a prospective GOELAMS study. Blood. 2012; 119(12):2943-8.
9. Le Bourgeois A, Lestang E, Guillaume T, Delaunay J, Ayari S, Blin N, et al. Prognostic impact of immune status and hematopoietic recovery before and after fludarabine, IV busulfan and antithymocyte globulins (FB2 regimen) reduced-intensity conditioning regimen (RIC) allogeneic stem cell transplantation (allo-SCT). Eur J Haematol. 2013; 90(3):177-86.
10. Aoudjhane M, Labopin M, Gorin NC, Shimoni A, Kolb HJ, Frassoni F, et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukaemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia. 2005; 19(12):2304-12.
11. Mohty M, Labopin M, Volin L, Gratwohl A, Socie G, Esteve J, et al. Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood. 2010;116(22): 4439-43.
12. Ghanem H, Kantarjian H, Ohanian M, Jabbour E. The role of clofarabine in acute myeloid leukemia. Leuk Lymphoma. 2013; 54(4):688-98.
13. Hijiya N, Barry E, Arceci RJ. Clofarabine in pediatric acute leukemia: current findings and issues. Pediatr Blood Cancer. 2012;59 (3):417-22.
14. Kantarjian H, Gandhi V, Cortes J, Verstovsek S, Du M, Garcia-Manero G, et al. Phase 2 clinical and pharmacologic study of clofara-bine in patients with refractory or relapsed acute leukemia. Blood. 2003;102(7):2379-86.
15. Martin MG, Uy GL, Procknow E, Stockerl-Goldstein K, Cashen A, Westervelt P, et al. Allo-SCT conditioning for myelodysplastic syndrome and acute myeloid leukemia with clofarabine, cytarabine and ATG. Bone Marrow Transplant. 2009;44(1):13-7.
16. Kirschbaum MH, Stein AS, Popplewell L, Delioukina M, Chen R, Nakamura R, et al. A phase I study in adults of clofarabine combined with high-dose melphalan as reduced-intensity conditioning for allogeneic transplantation. Biol Blood Marrow Transplant. 2012;18(3):432-40.
17. Van Besien K, Stock W, Rich E, Odenike O, Godley LA, O'Donnell PH, et al. Phase I-II study of clofarabine-melphalan-alemtuzum-ab conditioning for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012;18(6):913-21.
18. Chevallier P, Labopin M, Buchholz S, Ganser A, Ciceri F, Lioure B, et al. Clofarabine-con-taining conditioning regimen for allo-SCT in AML/ALL patients: a survey from the Acute Leukemia Working Party of EBMT. Eur J Haematol. 2012;89(3):214-9.
19. Greenberg P, Cox C, LeBeau M, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89(6):2079-88.
20. Chevallier P, Fornecker L, Lioure B, Bene MC, Pigneux A, Recher C, et al. Tandem versus single autologous peripheral blood stem cell transplantation as post-remission therapy in adult acute myeloid leukemia patients under 60 in first complete remission: results of the multicenter prospective phase III GOELAMS LAM-2001 trial. Leukemia. 2010;24(7):1380-5.
21. Huguet F, Leguay T, Raffoux E, Thomas X, Beldjord K, Delabesse E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: The GRAALL-2003 study. J Clin Oncol. 2009;27(6):911-8.
22. Beldjord K, Macintyre E, Lheritier V, Boulland ML, Leguay T, Thomas X, et al. Minimal residual disease at 3 months, combined to the presence of IKZF1 deletion in B-lineage or absence of NOTCH1 pathway muta tion in T-lineage, recapitulates the disease risk assessment in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: a GRAALL study. Blood. (AHS Annual Meeting Abstracts) 2011;118:abstract 572.
23. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912-9.
24. Schichman SA, Suess P, Vertino AM, Gray PS. Comparison of short tandem repeat and variable number tandem repeat genetic markers for quantitative determination of allogeneic bone marrow transplant engraft-ment. Bone Marrow Transplant. 2002;29 (3):243-8.
25. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999; 18(6):695-706.
26. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation. 1974;18(4):295-304.
27. Shulman H, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69 (2):204-17.
28. Valcarcel D, Martino R, Caballero D, Martin J, Ferra C, Nieto JB, et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol. 2008;26(4):577-84.
29. McClune BL, Weisdorf DJ, Pedersen TL, Tunes da Silva G, Tallman MS, Sierra J, et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol. 2010;28(11):1878-87.
30. Mageneau J, Tobai H, Pawarode A, Braun T, Peres E, Reddy P, et al. Clofarabine and busulfan conditioning facilitates engraft-ment and provides significant anti-tumor activity in non-remission hematologic malignancies. Blood. 2011;118(15):4258-64.
31. Martino R, Giralt S, Caballero MD, Mackinnon S, Corradini P, Fernandez-Aviles, et al. Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in acute lymphoblastic leukemia: a feasibility study. Haematologica. 2003;88(5): 555-60.
32. Ram R, Storb R, Sandmaier BM, Maloney DG, Woolfrey A, Flowers ME, et al. Non-myeloablative conditioning with allogene-ic hematopoietic cell transplantation for the treatment of high-risk acute lym-phoblastic leukemia. Haematologica. 2009; 96(8):1113-20.
33. Marks D, Wang T, Perez WS, Antin JH, Copelan E, Gale RP, et al. The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission. Blood. 2010;116(3):366-74.
34. Cho BS, Lee S, Kim YJ, Chung NG, Eom KS, Kim HJ, et al. Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: results of a prospective phase 2 study. Leukemia. 2009;23(10): 1763-70.
35. Bachanova V, Verneris MR, DeFor T, Brunstein CG, Weisdorf DJ, et al. Prolonged survival in adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord blood or sibling donor transplantation. Blood. 2009;113(13):2902-5.
36. Reed JC. Bcl-2 and the regulation of programmed cell death. J Cell Biol. 1994;124 (1-2):1-6.
37. Shigemi H, Yamauchi T, Tanaka Y, Ueda T. Novel leukemic cell lines resistant to clofara-bine by mechanisms of decreased active metabolite and increased antiapoptosis. Cancer Sci. 2013;104(6):732-9.
38. Mohty M, Blaise D, Labopin M, Milpied N, Furst S, Tabrizi R, et al. Fludarabine, IV busulfan and anti-thymocyte Globulins-based reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation (allo-SCT): results of a multicenter prospective trial. Blood. (ASH Annual Meeting Abstracts) 2012;120:abstract 1926.
39. Andersson BS, Valdez BC, de Lima M, Wang X, Thall P F, Worth LL, et al. Clofarabine± fludarabine with once daily IV busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. Biol Blood Marrow Tranplant. 2011;17(6):893-900.
40. Kebriaei P, Basset R, Ledesma C, Ciurea S, Parmar S, Shpall EJ, et al. Clofarabine combined with busulfan provides excellent disease control in adult patients with acute lymphoblastic leukemia undergoing allo-geneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012; 18(12):1819-26.
41. Valdez BC, Li Y, Murray D, Champlin RE, Andersson BS. The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodeling. Biochem Pharmacol. 2011;81(2):222-32.